The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020. * Identification period of the index period: 10/10/2019 to 04/30/2020 * Index date: Date of enrollment in the PSS program * Study Period: 10/10/2019 to 04/30/2020
Study Type
OBSERVATIONAL
Enrollment
18,457
All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
Novartis Investigative Site
East Hanover, New Jersey, United States
Number of patients with Primary plan type
The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance.
Time frame: Index date defined as the date of enrollment in the PSS program
Age
Age information of patients enrolled in the brolucizumab PSS program was reported
Time frame: Index date defined as the date of enrollment in the PSS program
Gender
Gender information of patients enrolled in the brolucizumab PSS program was reported
Time frame: Index date defined as the date of enrollment in the PSS program
Patient region (by state)
Distribution of patients across US states
Time frame: Index date defined as the date of enrollment in the PSS program
Provider region (by state)
Number of providers and their distribution across US states
Time frame: Index date defined as the date of enrollment in the PSS program
Insurance coverage
The insurance coverage details for all the patients with wet AMD was reported
Time frame: Index date defined as the date of enrollment in the PSS program
Number of patients with Secondary plan type
The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Index date defined as the date of enrollment in the PSS program
Disease Status
The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral
Time frame: Index date defined as the date of enrollment in the PSS program